Sangamo BioSciences to Focus on Advancing ZFP Therapeutic Pipeline at J.P. Morgan Healthcare Conference

“Sangamo has created a pipeline of innovative and proprietary ZFP Therapeutics for monogenic diseases and HIV/AIDS, designed not just to treat, but to provide cures for these diseases,” stated Mr. Lanphier.  “In 2013 we saw important progress in Sangamo’s preclinical pipeline and we expect to advance several of these programs into clinical testing by filing Investigational New Drug (IND) applications in 2014. Given the strength of Sangamo’s balance sheet, we are well positioned to accomplish our current development goals while continuing to expand Sangamo’s therapeutic pipeline.”

During his presentation, Mr. Lanphier will highlight recent activities including updates on:

• Sangamo’s SB-728-T program, a ZFP Therapeutic designed to provide functional control of  HIV/AIDS, and the ongoing SB-728-1101 study designed to maximize engraftment of ZFP nuclease (ZFN)-CCR5 modified CD4 T-cells;
• Sangamo’s In Vivo Protein Replacement Platform for the treatment and potential cure of  hemophilia and lysosomal storage disorders and proof of concept data in non-human primates;
• Positive data from the Shire-partnered Huntington’s disease program in animal models of the disease; and
• Preclinical data and specific details of the ZFP Therapeutic approach to provide a potential cure for both sickle cell disease and beta-thalassemia.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 and Phase1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. As part of its acquisition of Ceregene Inc., Sangamo acquired a fully-enrolled and funded, double-blind, placebo-controlled Phase 2 trial to evaluate NGF-AAV (CERE-110) in Alzheimer’s disease. Sangamo’s other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington’s disease and  hemoglobinopathies such as beta-thalassemia and sickle cell anemia. Sangamo’s core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington’s disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciencesand Sigma-Aldrich Corporation. For more information about Sangamo, visit the company’s website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.

This press release may contain forward-looking statements based on Sangamo’s current expectations. These forward-looking statements include, without limitation, references relating to expected timing of filing of IND applications, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo’s ZFP technology platform for the treatment and cure of monogenic diseases and HIV/AIDS, including preclinical data from Sangamo’s  programs for hemophilia, lysosomal storage disorders, Huntington’s disease, sickle cell disease and beta-thalassemia.. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of our clinical trials, whether the clinical trials will validate and support the tolerability and efficacy of ZFNs, technological challenges, Sangamo’s ability to develop commercially viable products and technological developments by our competitors. For a more detailed discussion of these and other risks, please see Sangamo’s public filings with the Securities and Exchange Commission, including the risk factors described in Sangamo’s Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.

SOURCE Sangamo BioSciences, Inc.